Safety, Tolerability, and Efficacy of MN-001 in Patients With Idiopathic Pulmonary Fibrosis

על הניסוי

This is a randomized, placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension phase to evaluate the efficacy, safety, and tolerability of MN-001 in patients diagnosed with moderate to severe idiopathic pulmonary fibrosis (IPF). Participants were randomly assigned to receive MN-001 or matching placebo twice daily over a 26-week period. A total of 15 participants were enrolled.

צפו ב-NCT02503657 ב-ClinicalTrials.gov ←

קישורים קשורים